NEW YORK PHARMA FORUM

TUESDAY, JANUARY 31, 2012

TOPIC: **The Biosimilars/Follow-on Biologics Landscape**

SPEAKERS: **Andrew Bourgoin,** Pharmaceutical Research Analyst, Thomson Reuters

Diem Nguyen, Ph.D., General Manager
Biosimilars Established Products Business Unit, Pfizer, Inc.

Nigel J. Rulewski, MD, Vice President
Strategic Drug Development Group, Quintiles, Inc.

The Biologics Price Competition and Innovation Act passed last year by Congress paves the way for regulatory approval and marketing of follow-on biologic drugs in the U.S. The availability of this new category of drugs is projected to lead to savings to private health plans, Medicare and Medicaid of $300 billion or more in the U.S. by 2029. A big part of this equation is patent expiration of some top-selling biologic drugs in the next few years. It is crucial for biopharma companies to understand the shape of the new follow-on biologics market to position themselves for the future.

New York Pharma Forum has gathered a panel of three experts to discuss the players, strategies and regulatory terrain for the new follow-on biologics market.